3. November 2009 08:00
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.
- Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No.: A106, "A Phase 1 study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)," Halls C-D, 2nd floor.
- Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No.: A156, "Mechanisms of resistance to Aurora kinase B inhibitors in leukemia: development and characterization of in vitro models," Halls C-D, 2nd floor.
- Poster Session: Wednesday, November 18, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No: C75, "A novel multi-targeted Aurora A and VEGFR2 kinase inhibitor, ENMD-2076, demonstrates synergistic antiproliferative and proapoptotic effects in combination with chemotherapy and trastuzumab in breast cancer cell lines," Halls C-D, 2nd floor.
SOURCE EntreMed
76e948f7-1682-41ef-9592-c27fcfaad8a9|0|.0
Posted in: Drug Trial News | Medical Condition News | Pharmaceutical News
Tags: Arthritis, Breast Cancer, Cancer, Cell, Chemotherapy, Kinase Inhibitor, Leukemia, Multiple Myeloma, Myeloid Leukemia, Pathology, Rheumatoid Arthritis
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Subscribe